Phase 1Status unknown
Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects.
A Phase I, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability Profile of Topical Cream SNG100 for 14 Days of Treatment in Moderate Atopic Dermatitis Subjects.
- Sponsor
- Seanergy Dermatology Ltd. (Industry)
- Enrollment
- 66 planned
- Conditions
- Atopic Dermatitis
- Interventions
- Hydrocortisone Acetate 1% Cream; Mometasone Furoate; SNG100
- Ages
- children, adults, older adults
- Registry
- NCT04615962
Full record on ClinicalTrials.gov
From the registry
The investigators aimed to understand better the efficacy in a randomized, double-blind, intraindividual design trial in 66 participants with AD treated with SNG100, and 2 different strengths of topical steroids hydrocortisone and the medium potent mometasone furoate cream.
Primary outcomes
- Side Effects AE's and SAE's
History
Primary completion
Started
Registered